BioSante to begin Phase I trial of melanoma vaccine at Johns Hopkins
This article was originally published in Scrip
Executive Summary
BioSante Pharmaceuticals has signed a deal providing an exclusive worldwide licence of its melanoma cancer vaccine programme to the John P Hussman Foundation, and the charitable group will be funding early-stage trials at the US based Johns Hopkins Cancer Center.